Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction

• Published in: The Journal of biological chemistry Vol. 298; no. 12; p. 102625
• Main Authors: Magat, Jenna, Jones, Samantha, Baridon, Brian, Agrawal, Vishal, Wong, Hio, Giaramita, Alexander, Mangini, Linley, Handyside, Britta, Vitelli, Catherine, Parker, Monica, Yeung, Natasha, Zhou, Yu, Pungor, Erno, Slabodkin, Ilya, Gorostiza, Olivia, Aguilera, Allora, Lo, Melanie J., Alcozie, Saida, Christianson, Terri M., Tiger, Pascale M.N., Vincelette, Jon, Fong, Sylvia, Gil, Geuncheol, Hague, Chuck, Lawrence, Roger, Wendt, Daniel J., Lebowitz, Jonathan H., Bunting, Stuart, Bullens, Sherry, Crawford, Brett E., Roy, Sushmita M., Woloszynek, Josh C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-12-2022; American Society for Biochemistry and Molecular Biology
• Subjects: Animals; Brain - metabolism; Brain Diseases - metabolism; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; enzyme replacement therapy; Heparitin Sulfate - metabolism; Humans; Hydrolases - metabolism; lysosomal storage disease; Lysosomes - metabolism; Mice; mucopolysaccharidosis; Mucopolysaccharidosis III - drug therapy; Mucopolysaccharidosis III - metabolism; Pilot Projects; rhSGSH; Sanfilippo; enzyme replacement therapy; LC-PRM; lysosomal storage disease; Sanfilippo; ERT; M6P; MS; mucopolysaccharidosis; CNS; CHO; HS; MEF; SEC; MPS; rhSGSH; CSF; h.e.d; HS-NRE; ICV
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1016/j.jbc.2022.102625

Mucopolysaccharidosis type IIIA (MPS IIIA) is a lysosomal storage disorder caused by N-sulfoglucosamine sulfohydrolase (SGSH) deficiency. SGSH removes the sulfate from N-sulfoglucosamine residues on the nonreducing end of heparan sulfate (HS-NRE) within lysosomes. Enzyme deficiency results in accumulation of partially degraded HS within lysosomes throughout the body, leading to a progressive severe neurological disease. Enzyme replacement therapy has been proposed, but further evaluation of the treatment strategy is needed. Here, we used Chinese hamster ovary cells to produce a highly soluble and fully active recombinant human sulfamidase (rhSGSH). We discovered that rhSGSH utilizes both the CI-MPR and LRP1 receptors for uptake into patient fibroblasts. A single intracerebroventricular (ICV) injection of rhSGSH in MPS IIIA mice resulted in a tissue half-life of 9 days and widespread distribution throughout the brain. Following a single ICV dose, both total HS and the MPS IIIA disease-specific HS-NRE were dramatically reduced, reaching a nadir 2 weeks post dose. The durability of effect for reduction of both substrate and protein markers of lysosomal dysfunction and a neuroimmune response lasted through the 56 days tested. Furthermore, seven weekly 148 μg doses ICV reduced those markers to near normal and produced a 99.5% reduction in HS-NRE levels. A pilot study utilizing every other week dosing in two animals supports further evaluation of less frequent dosing. Finally, our dose–response study also suggests lower doses may be efficacious. Our findings show that rhSGSH can normalize lysosomal HS storage and markers of a neuroimmune response when delivered ICV.